https://orcid.org/0000-0002-7423-0111
Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Paul K. S. Chan, Martin C. S. Wong, Macy Chan, Karen Ching, Nikolaos Giannelos & Cheryl Ng. (2023) Public health impact of herpes zoster vaccination on older adults in Hong Kong. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Nikolaos Giannelos, Cheryl Ng & Desmond Curran. (2023) Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Ru Han, Jorge A. Gomez, Bruna de Veras, Thatiana Pinto, Adriana Guzman-Holst, Javier Nieto & Désirée A. M. van Oorschot. (2023) How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Articles from other publishers (4)
Nicolas Dauby, Christian Motet, Agnès Libois & Charlotte Martin. (2023)
The value of herpes zoster prevention in people aging with
HIV
: A narrative review
. HIV Medicine 24:12, pages 1190-1197.
Crossref
Crossref
Desmond Curran, T. Mark Doherty, Nicolas Lecrenier & Thomas Breuer. (2023) Healthy ageing: Herpes zoster infection and the role of zoster vaccination. npj Vaccines 8:1.
Crossref
Crossref
David Singer, Ahmed Salem, Nikita Stempniewicz, Siyu Ma, Sara Poston & Desmond Curran. (2023) The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50–59 years. Vaccine 41:37, pages 5360-5367.
Crossref
Crossref
Lida Teng, Akiko Mizukami, Cheryl Ng, Nikolaos Giannelos, Desmond Curran, Tomohide Sato, Christa Lee & Taizo Matsuki. (2022) Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults. Dermatology and Therapy 12:6, pages 1447-1467.
Crossref
Crossref